Exelixis Inc. (Nasdaq: EXEL) reported disappointing results from a late stage study of its prostate cancer treatment cabozantinib and announced a 70% reduction in its workforce. Shares of the biotechnology firm plummeted $2.25 to $1.89.
Exelixis reports disappointing trial results
September 02, 2014 at 14:38 PM EDT
